Skip to main content

Table 4 Course of Symptoms as assessed in 21 ovarian cancer patients with the ovarian cancer-specific module (OV-28) of the EORTC Quality of Life core questionnaire

From: Monitoring physical and psychosocial symptom trajectories in ovarian cancer patients receiving chemotherapy

EORTC QLQ-OV28c

 

Baselinea

CT 3b

CT 6

AC1b

AC2

constant term/

beta coefficient

Abdominal Symptoms (AS)

41.9 (28.1)

21.8

29.2

20.5

13.5

(21.7)

36.8/-3.0

t = -2.72; p = 0.009

Peripheral Neuropathy (PN)

32.8 (26.2)

37.7

39.2

37.7

23.1 (26.1)

35.3/-0.5

t = -0.39; p = 0.697

Other Chemotherapy-related Side Effects (CSE)

30.2 (33.8)

29.3

29.8

23.0

1.6

(2.7)

42.4/-5.7

t = -5.97; p < 0.001

Hormonal/menopausal Symptoms (HS)

34.1 (35.1)

22.2

26.5

31.5

22.2 (31.2)

30.2/-0.8

t = -0.55; p = 0.587

Body Image (BI)

73.0 (33.1)

74.5

84.3

75.0

77.8 (25.0)

74.2/0.8

t = 0.68; p = 0.502

Attitudes towards Disease

and Treatment (AT)

26.1 (22.6)

39.5

56.9

53.7

66.7 (24.6)

27.1/5.4

t = 5.30; p < 0.001

Sexual Functioning (SF)

47.9 (21.9)

64.3

48.8

57.3

57.4 (12.8)

48.9/1.0

n = 8

  1. a Baseline (CT1)
  2. b CT chemotherapy cycle, AC aftercare
  3. c Reference values (ovarian cancer patients, all stages) [54]: AS = 21.9 (22.1), PN = 17.1 (27.2), CSE = 19.5 (20.5), HS = 25.8 (30.3), BI = 22.2 (27.4), AT = 42.3 (30.6)